Monadia (Mometasone Furoate)

Mometasone furoate, the active ingredient in Monadia, is a corticosteroid presented as a nasal spray for nasal administration. It is indicated for the management of allergic rhinitis and nasal polyps, where it reduces mucosal inflammation and alleviates symptoms such as congestion, sneezing, and nasal discharge in adult and adolescent patients.

GNH USA supplies Monadia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance.

Monadia (mometasone furoate) is a nasal corticosteroid used to treat inflammatory conditions of the nasal passages.

Allergic rhinitis: reduces nasal inflammation and symptom severity. Nasal polyps: decreases polyp size and improves nasal airflow. Seasonal allergic rhinitis: alleviates congestion, sneezing and runny nose during allergen exposure.

Common Side Effects: - Nasal irritation or burning sensation - Headache - Epistaxis (nosebleeds) - Throat irritation or dryness - Cough - Altered taste perception

Serious or Rare Side Effects: - Adrenal suppression - Cataracts or glaucoma - Fungal infection of the nasal mucosa - Severe allergic reaction (anaphylaxis) - Perforation of the nasal septum - Vision changes or ocular pressure increase

Before using Monadia, consider the following precautions: - Assess for active nasal infection: avoid use until infection is resolved. - Avoid in patients with known hypersensitivity to mometasone furoate or formulation excipients. - Use the lowest effective dose: follow prescriber instructions to minimize systemic exposure. - Monitor for signs of adrenal insufficiency, especially with prolonged high‑dose therapy. - Caution in patients with glaucoma or cataracts: regular ophthalmologic evaluation may be needed. - Store at room temperature: keep in the original container, protect from moisture and heat.

Mometasone furoate nasal spray may interact with other medications.

Major Interactions (Avoid): - Systemic corticosteroids: increased risk of systemic steroid effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise mometasone exposure. - Live vaccines: potential reduction in vaccine efficacy due to immunosuppression.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, ritonavir): may modestly increase exposure. - Antifungal azoles with moderate inhibition: monitor for local irritation. - Diuretics: watch for electrolyte disturbances if systemic absorption occurs.